The bee venom active compound melittin protects against bicuculline-induced seizures and hippocampal astrocyte activation in rats

Author(s)

Soares-Silva, Beatriz ; Araujo Beserra-Filho, Jose Ivo ; Araujo Morera, Pamela Maria ; Custodio-Silva, Ana Claudia ; Maria-Macedo, Amanda ; Silva-Martins, Suellen ; Alexandre-Silva, Vanessa ; Silva, Sara Pereira ; Silva, Regina Helena ; Ribeiro, Alessandra Mussi

• Document type: Journal article
• Source: Neuropeptides; v. 91, p. 8-pg., 2022-02-01.

Abstract

Epilepsy is a chronic neuropathology characterized by an abnormal hyperactivity of neurons that generate recurrent, spontaneous, paradoxical and synchronized nerve impulses, leading or not to seizures. This neuro-logical disorder affects around 70 million individuals worldwide. Pharmacoresistance is observed in about 30% of the patients and long-term use of antiepileptics may induce serious side effects. Thus, there is an interest in the study of the therapeutic potential of bioactive substances isolated from natural products in the treatment of epilepsy. Arthropod venoms contain neurotoxins that have high affinity for molecular structures in the neural tissue such as receptors, transporters and ion channels both in glial and neuronal membranes. This study evaluated the potential neuroprotective effect of melittin (MEL), an active compound of bee venom, in the bicuculline-induced seizure model (BIC) in rats. Male Wistar rats (3 months, 250-300 g) were submitted to surgery for the implantation of a unilateral cannula in the lateral ventricle. After the recovery period, rats received a microinjection of saline solution or MEL (0.1 mg per animal). Firstly, rats were evaluated in the open field (20 min) and in the elevated plus maze (5 min) tests after received microinjection of saline or MEL. After, 30 min later animals received BIC (100 mg/ml) or saline, and their behaviors were analyzed for 20 min in the open field according to a seizure scale. At the end, rats were euthanized, brains collected and processed to glial fibrillary acidic protein (GFAP) immunohistochemistry evaluation. No changes were observed in MEL-treated rats in the open field and elevated plus maze. However, 90% of MEL-treated animals were protected against seizures induced by BIC. There was an increase in the latency for the onset of seizures, accompanied by a reduction of GFAP-immunoreactivity cells in the dentate gyrus and CA1. Thus, our study suggests that MEL has an anticonvulsant potential, and further studies are needed to elucidate the mechanisms involved in this action. (AU)

• FAPESP's process: 15/20785-8 - Bioprospecting of natural products with potential neuroprotective activity in animal models of Epilepsy and Parkinson's disease.
• Grantee: Alessandra Mussi Ribeiro
• Support Opportunities: Regular Research Grants
• FAPESP's process: 15/03354-3 - PATHOPHYSIOLOGICAL MECHANISMS AND NEUROPROTECTIVE INTERVENTIONS IN A PROGRESSIVE ANIMAL MODEL OF PARKINSON'S DISEASE
• Grantee: Regina Helena da Silva
• Support Opportunities: Regular Research Grants